Posts Tagged ‘drug’
BOSTON (Reuters) – Osiris Therapeutics Inc said on Thursday that Canadian health regulators have approved its treatment for acute graft-versus host disease in children, making it the first stem cell drug to be approved for a systemic disease anywhere in the world.
Incoming search terms:
Related Posts:
 | US $102.94 End Date: Saturday May-26-2012 11:49:45 PDT Buy It Now for only: US $102.94 Buy it now | Add to watch list |
Healthcare Informatics and Information Synthesis: Developing and Applying...
 | US $206.78 End Date: Sunday May-27-2012 3:08:25 PDT Buy It Now for only: US $206.78 Buy it now | Add to watch list |
Managing Health Care Information Systems by Frances ...
 | US $20.95 End Date: Sunday May-27-2012 4:53:45 PDT Buy It Now for only: US $20.95 Buy it now | Add to watch list |
Related Posts:
ZURICH (Reuters) – Swiss drugmaker Roche has ended efforts to develop a heart disease drug that according to some industry analysts could have achieved $ 10 billion annual sales, after poor results from a late stage trial.
Incoming search terms:
Related Posts:
The Food and Drug Administration on Tuesday approved a new treatment for Gaucher disease, a rare genetic disorder that can cause liver and neurological problems.
Incoming search terms:
- Elelyso
- fda approves protalix’s gaucher drug elelyso laura clark
- president obama new law to install a microchip
Related Posts:
Two companies have teamed up to market fingerprint-based drug testing to police, prisons, and, they hope, American companies.
Related Posts:
 | US $107.61 End Date: Friday May-25-2012 16:45:40 PDT Buy It Now for only: US $107.61 Buy it now | Add to watch list |
Project Management for Healthcare Information Techn...
 | US $82.10 End Date: Saturday May-26-2012 4:51:03 PDT Buy It Now for only: US $82.10 Buy it now | Add to watch list |
Strategy and Architecture of Health Care Information Systems - Hardcover
 | US $10.48 End Date: Saturday May-26-2012 5:51:56 PDT Buy It Now for only: US $10.48 Buy it now | Add to watch list |
Incoming search terms:
- obama approves microchip in 2013
- obama approves microchip for april 2013
- april 2013 obama approves microchip
- sanitary reform microchip law obama
- sanitary reform 2013
Related Posts:
(PRWEB) April 17, 2012
Nationwide, drugs used for acute cardiac care such as Sodium Bicarbonate, analgesics like morphine, and other common drugs like Epinephrin, Heparin, Dopamine, Fentanyl, Lidocaine, Magnesium Sulfate, and many others are on back order or are not available to health care providers, as manufacturers of the generic drugs face cost and production interferences or are stopping production altogether, cites a recent CBS article: http://tinyurl.com/7cl4266
The Missouri EMS Association, MEMSA, wishes to highlight the fact that, on the national level, EMS providers have the most difficulty in obtaining the needed drugs in the present shortage because unlike most hospitals, pre-hospital emergency health care providers are generally smaller entities without significant buying power.
For example, emergency patients requiring rapid sequence intubation, which provides an emergency airway, require the anesthesia known as Etomidate, an expensive drug not currently available. Paramedics and EMTs also do not have access to other life-saving medications needed to treat patients. Some agencies recently reported as little as a two-day supply of Midazolam or Versed, a sedative used to treat seizures.
This is a real drug shortage issue, where critical life and health needs cannot be met, said Dr. Joseph Salomone, an EMS medical director and representative of the Missouri EMS Association. EMS provides time critical medical attention in emergency situations. Even where there may be an option to temporarily replace one drug for another, the change creates a lot of interference in the preparation and administration of medications such as dosage and concentration changes, packaging changes, which means new points for error so this is also a patient safety issue.
The off patent generic drugs generally yield a narrow profit margin for manufacturers, some of which are forced to stop production due to FDA oversight issues such as inspections which create cost obstacles for producers. Some drug companies have apparently stopped making certain medicines in a dispute over new federal regulations. Other potential causes for the medication shortage may be unanticipated increases in demand or shortages of raw materials.
The number of drug shortages in the United States nearly tripled between 2005 and 2010 and are becoming more severe and more frequent.
In order to to clarify the scope of the problem and share ways that EMS systems are coping with the drug shortages, the National Association of Emergency Medical Technicians, NAEMT, will participate in a meeting on April 16 in Washington, D.C. sponsored by the Department of Health and Human Services that will bring together representatives from federal agencies and national EMS organizations. NAEMT is also offering EMS practitioners a survey to capture drug shortage data at http://www.surveymonkey.com/s/emsdrugshortage.
About MEMSA: The Missouri EMS Association is a statewide nonprofit EMS association dedicated to supporting EMS professionals, members and agencies at the legislative, educational, membership and communications levels. Ensuring that EMS professionals receive quality pre-hospital support and education in the state of Missouri, assures quality pre-hospital care for the public. http://www.memsa.org.
Other MEMSA News: http://www.prweb.com/releases/2012/3/prweb9337434.htm
http://www.facebook.com/memsafans OR http://www.causes.com/memsa
Contact: Jessica Anderson Phone: 573-761-9911 Email: memsa(at)memsa(dot)org
MEMSA 425 E. High Street Jefferson City, Missouri 65101
Related Posts:
Swiss drug maker Roche Holding AG reported Thursday that sales dipped one percent to 11.03 billion Swiss francs ($ 12.05 billion) in the first quarter, while hinting that it might be prepared to raise its offer for U.S. diagnostics firm Illumina Inc.
Related Posts:
Related Posts:
AVI BioPharma Inc’s shares could get a boost if its drug targeting treatment for a rare fatal form of muscular dystrophy proves to be effective in clinical drug trials, according to an article in the April 2 edition of Barron’s.